John McHutchison, Assembly CEO (Getty Images)
June 19, 2020 08:13 AM EDTUpdated 09:45 AM
Deals
R&D

Ab­b­Vie sweeps out ex­per­i­men­tal gas­tro drugs in a post-merg­er pipeline cleanup. And they can like­ly be yours for the right price

John Carroll

Editor & Founder

Ab­b­Vie nev­er want­ed all the pipeline projects on dis­play at Al­ler­gan. And now the phar­ma gi­ant is writ­ing off an $80 mil­lion in­vest­ment in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times